Merck raises FY profit outlook as Q3 revenue climbs 5% to $18.1B
Key points
- Merck (NYSE:MRK) reported third-quarter 2026 revenue of $18.1 billion, up 5% year over year, and adjusted earnings per share of $2.49, above the $2.09 analyst consensus.
- Keytruda sales, including Keytruda Qlex, reached $8.6 billion, while Winrevair sales climbed 93% to $694 million.
- Merck increased its 2026 adjusted EPS guidance to $2.77–$2.82 per share and narrowed its revenue outlook to $66.8 billion–$67.3 billion.
Merck (NYSE:MRK) reported third-quarter 2026 revenue of $18.1 billion, up 5% year over year, as growth in key pharmaceutical products supported results.
The company beat analyst expectations and raised its full-year adjusted profit outlook.
GAAP net income reached $5.07 billion, equivalent to $2.04 per share.
Adjusted earnings per share, which excludes certain items, increased to $2.49, exceeding the analyst consensus of $2.09.
Keytruda, including Keytruda Qlex, generated $8.6 billion in sales, up 6% year over year.
The subcutaneous formulation Keytruda Qlex contributed $830 million.
Winrevair sales increased 93% to $694 million, while Gardasil and Gardasil 9 generated approximately $2 billion in sales, up 14% excluding foreign exchange effects.
Animal Health revenue rose 4% to $1.7 billion.
Looking ahead, Merck raised its full-year 2026 adjusted EPS guidance to $2.77–$2.82 per share, from the previous range of $2.66–$2.76.
The revised outlook includes a one-time charge of $0.12 per share related to a licensing agreement with SciBrunch.
The company also narrowed its full-year revenue guidance to $66.8 billion–$67.3 billion.
Frequently asked questions
More from United States
Eli Lilly Q3 revenue surges 39% to $24.4 billion as guidance rises
Enterprise Products Q3 EBITDA jumps 16% to $2.8 billion
KBR Q3 revenue rises 5% to $2 billion as adjusted EBITDA grows 12%
Enerflex Q3 free cash flow rises to $102 million as net earnings climb
WTW Q3 revenue rises 8% to $2.46 billion as AI savings plan advances
Axalta reports higher Q3 sales but lower net income of $95M
